| ID | 58279 |
| JaLCDOI | |
| フルテキストURL | |
| 著者 |
Abe, Yoshiyuki
Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine
Fujibayashi, Kazutoshi
Medical Technology Innovation Center, Juntendo University
Nishizaki, Yuji
Medical Technology Innovation Center, Juntendo University
Yanagisawa, Naotake
Medical Technology Innovation Center, Juntendo University
Nojiri, Shuko
Medical Technology Innovation Center, Juntendo University
Kon, Takayuki
Department of Internal Medicine and Rheumatology, Juntendo University Nerima Hospital
Tada, Kurisu
Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine
Yamaji, Ken
Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine
Tamura, Naoto
Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine
|
| 抄録 | Glucocorticoids (GCs) have long played a central role in the treatment of systemic lupus erythematosus (SLE), but these drugs have many adverse effects. We will determine whether rapid weekly GC tapering is non-inferior to conventional biweekly tapering in patients with severe SLE. This is a randomized, open-label, multicenter controlled trial. The primary outcome is the relapse-free survival rate at 52 weeks. The main secondary outcome is the prevalence of the Lupus Low Disease Activity State at 52 weeks. The trial will determine the optimal method of tapering GCs in patients with severe SLE.
|
| キーワード | systemic lupus erythematosus
relapse-free survival rate
glucocorticoid, tapering
Lupus Low Disease
Activity State
|
| Amo Type | Clinical Study Protocol
|
| 出版物タイトル |
Acta Medica Okayama
|
| 発行日 | 2020-04
|
| 巻 | 74巻
|
| 号 | 2号
|
| 出版者 | Okayama University Medical School
|
| 開始ページ | 179
|
| 終了ページ | 183
|
| ISSN | 0386-300X
|
| NCID | AA00508441
|
| 資料タイプ |
学術雑誌論文
|
| 言語 |
英語
|
| 著作権者 | CopyrightⒸ 2020 by Okayama University Medical School
|
| 論文のバージョン | publisher
|
| 査読 |
有り
|
| PubMed ID | |
| Web of Science KeyUT | |
| NAID |
